Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

776.46 +21.55 (+2.85%)
Streaming Delayed Price Updated: 2:34 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
News headline image
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The Great Reversal: Tariffs Ignite Goods Inflation as Services Cool in Latest PCE Data
The latest Personal Consumption Expenditures (PCE) price index data has revealed a significant shift in the U.S. inflationary landscape, presenting a complex puzzle for the Federal Reserve. As of early... 
Via MarketMinute
Topics Artificial Intelligence Economy World Trade
News headline image
Regeneron (REGN) Q1 2025 Earnings Call Transcript ↗
Regeneron (REGN) Q1 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Supply Chain
Regeneron Stock Slips Premarket Even After Wall Street Lifts Targets On Strong Q4 — What’s Weighing On The Stock? ↗
Via Stocktwits
Regeneron Pharmaceuticals (NASDAQ:REGN) Reports Q4 2025 Earnings Beat Amid Product Transition ↗
Via Chartmill
Topics Earnings
News headline image
Regeneron (REGN) Q2 2025 Earnings Call Transcript ↗
Regeneron (REGN) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Regeneron (REGN) Q4 2024 Earnings Call Transcript ↗
Regeneron (REGN) Q4 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Regeneron (REGN) Q3 2024 Earnings Call Transcript ↗
Regeneron (REGN) Q3 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment of Serious Retinal Diseases
New presentations include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion, as well as full primary results from the Phase 3b ELARA trial in patients treated... 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
This $24 Million Buy Amid a 45% Stock Drop Signals Conviction in a High-Margin Data Business ↗
FactSet delivers integrated financial data and analytics to institutional clients, supporting investment decisions worldwide. 
Via The Motley Fool
News headline image
Regeneron (REGN) Q4 2025 Earnings Call Transcript ↗
Regeneron (REGN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
These S&P500 stocks that are showing activity before the opening bell on Friday. ↗
Via Chartmill
News headline image
Regeneron’s New Growth Engine Is Starting To Show – But Core Eylea Weakness Weighs On REGN Stock ↗
Fourth-quarter revenue increased 3% from a year earlier to $3.88 billion, topping Wall Street expectations of $3.78 billion, according to Fiscal.ai data. 
Via Stocktwits
News headline image
Regeneron (NASDAQ:REGN) Posts Better-Than-Expected Sales In Q4 CY2025
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Streets expectations in Q4 CY2025, with sales up 2.5% year on year to $3.88 billion. Its non-GAAP profit of $11.44 per share was... 
Via StockStory
News headline image
Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings To Watch: Regeneron (REGN) Reports Q4 Results Tomorrow
Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
News headline image
2 Healthcare Stocks Poised for a Comeback in 2026 ↗
Don't wait too long to press the buy button on these comeback stories. 
Via The Motley Fool
News headline image
GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics
In a bold strategic opening to the 2026 fiscal year, pharmaceutical giant GSK (NYSE:GSK) has announced a definitive agreement to acquire RAPT Therapeutics (Nasdaq:RAPT) for approximately $2.2 billion.... 
Via MarketMinute
Topics Intellectual Property
News headline image
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗
Via MarketBeat
Topics ETFs
News headline image
3 Profitable Stocks We Think Twice About
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
1 Mooning Stock with Exciting Potential and 2 Facing Headwinds
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
Topics Economy Energy
News headline image
Regeneron Just Moved From Underperform To Buy - Here&#39;s Why ↗
Could the tide be turning for Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) after a surprising shift in analyst sentiment? 
Via Benzinga
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
Why Regeneron (REGN) Stock Is Trading Up Today
Shares of biotech company Regeneron (NASDAQ:REGN) jumped 2.9% in the morning session after Bank of America Securities upgraded its rating on the company's stock from 'Underperform' to 'Buy' and... 
Via StockStory
Topics Artificial Intelligence
News headline image
Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
3 Reasons to Avoid REGN and 1 Stock to Buy Instead
What a fantastic six months it’s been for Regeneron. Shares of the company have skyrocketed 47.6%, hitting $774.98. This was partly due to its solid quarterly results, and the performance may have... 
Via StockStory
News headline image
Discover which S&P500 stocks are making waves on Tuesday. ↗
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
3 Cash-Heavy Stocks We Approach with Caution
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
News headline image
The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax
As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ:... 
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.